Table 3. Details and summary of the diagnostic performance of different studies using LAMP for VL diagnosis compared to our study.
Studies | |||||
---|---|---|---|---|---|
Ghasemian et al. [28]a |
Verma et al. [29]b |
Verma et al. [30]c |
Khan et al. [31]d |
This studye | |
Country | Iran | India | India | Bangladesh | Sudan |
LAMP target | kDNA | kDNA | kDNA | kDNA | kDNA and 18SrRNA |
Primer specificity | L. infantum | L. donovani | L. donovani, L. major, L. tropica | L. donovani | Leishmania genus |
Study population | 47 VL cases 40 controls |
55 VL cases 68 controls |
66 VL cases 100 controls |
75 VL cases 101 controls |
185 VL suspects |
Clinical specimen tested | Buffy coat | Whole blood BMA |
Whole blood BMA |
Buffy coat | Whole blood Buffy coat |
DNA purification method | QIAamp Mini Kit (QIAgen) | QIAamp Mini Kit (QIAgen) | QIAamp Mini Kit (QIAgen) | QIAamp Mini Kit (QIAgen) | QIAamp Mini Kit (QIAgen) and Boil & Spin |
Reference test | DAT (>1:3200) and BMA microscopy | BMA microscopy and qPCR on blood and BMA | rK39 RDT-positive patients confirmed by qPCR | Spleen aspirate microscopy | Lymph node aspirate microscopy |
Sensitivity | BC 93.60% | WB 96.4% BMA 100% |
WB 96.6% BMA 100% |
BC 90.70% | WB-B&S 97.6% WB-QIA 100% BC-B&S 95.2% BC-QIA 97.6% |
Specificity | 100% | 98.5% | 100% | 90.7% | 99.01 |
a Controls in [28]: 30 healthy controls from non-endemic area and 10 non-VL patients (malaria, TB, toxoplasmosis, hepatitis herpes virus). b Controls in [29]: 34 HC-E, 5 malaria, 5 TB, 18 leprosy, 6 fungal diseases. c Controls in [30]: 24 HC-E, 38 HC-NE, 7 malaria, 7 TB, 18 leprosy, 6 fungal diseases. d Controls in [31]: 25 HC-E, 26 HC-NE, 25 TB, 25 other diseases. e Data from the 185 VL suspects tested by all methods.
BC: buffy coat. BMA: bone marrow aspirate. B&S: boil & spin. DAT: direct agglutination test. HC-E: healthy controls from endemic region. HC-NE: healthy controls from non-endemic region. kDNA: kDNA minicircles. QIA: QIAamp DNA Mini Kit. VL: visceral leishmaniasis. WB: whole blood.